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Objectives: Pneumocystis jirovecii pneumonia (PCP) is an AIDS-defining illness. In
patients with HIV, the benefit of PCP prophylaxis is well-defined when the CD4 T-cell
count decreases below 200 cells/µL. In other immunocompromised patients, the value
of PCP prophylaxis is not always as well-established. This study aimed to describe the
epidemiology of PCP in recent years and assess how many patients with PCP did or did
not receive prophylaxis in the month preceding the infection.
Material and Methods: A multicenter retrospective study was performed in 3 tertiary
care hospital. A list of patients that underwent broncho-alveolar lavage sampling and
Pneumocystis jirovecii (PJ) PCR testing was retrieved from the microbiology laboratories.
An in-house PJ quantitative PCR (qPCR) was used in each center. A cycle threshold (Ct)
value of≤28.5–30 was considered a probable PCP. For patients with a positive PJ qPCR
but above this threshold, a predefined case definition of possible PCP was defined as
a qPCR Ct value ≤34–35 and both of the following criteria: 1. Clinical and radiological
features compatible with PCP and 2. The patient died or received PCP therapy and
survived. Patient files from those with a qPCR Ct value ≤35 were reviewed to determine
whether the patient fulfilled the case definition and if PCP prophylaxis had been used
in the weeks preceding the PCP. Disease-specific guidelines, as well as hospital-wide
guidelines, were used to evaluate if prophylaxis could be considered indicated.
Results: From 2012 to 2018, 482 BAL samples were tested. Two hundred and four had
a qPCR Ct value ≤35 and were further evaluated: 90 fulfilled the definition of probable
and 63 of possible PCP while the remaining 51 were considered colonized. Seventy-four
percentages of the patients with PCPwere HIV-negative. Only 11 (7%) of the 153 patients
had received prophylaxis, despite that in 133 (87%) cases prophylaxis was indicated
according to guidelines.
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Conclusion: In regions where HIV testing and treatment is available without restrictions,
PCP is mainly diagnosed in non-HIV immunocompromised patients. More than four
out of five patients with PCP had not received prophylaxis. Strategies to improve
awareness of antimicrobial prophylaxis guidelines in immunocompromised patients are
urgently needed.
Keywords: Pneumocystic jirovecii pneumonia, Pneumocystis jiroveci (carinii) pneumonia, prophylaxis,
Trimetoprim- sulfamethoxazole, immunocompromidsed patients
INTRODUCTION
Pneumocystis jirovecii (PJ), formerly known as Pneumocystis
carinii species, is a unicellular eukaryotic and ubiquitous yeast-
like fungus and is the cause of Pneumocystis jirovecii pneumonia
(PCP), a life-threatening opportunistic disease (Stern et al., 2014).
It is a well-established complication in HIV-positive patients but
with the advent of combined antiretroviral therapy (cART) and
the use of prophylaxis in HIV-positive patients, the epidemiology
shifted to non-HIV immunocompromised hosts in countries
where HIV testing and access to cART is in place. The non-HIV
infected immunocompromised host encompasses patients after
a solid organ transplant (SOT), allogeneic hematopoietic stem
cell transplant recipients, patients receiving immunosuppressive
therapies for autoimmune and inflammatory conditions, with
genetic primary immune deficiency disorders and to a lesser
extent those treated for solid malignancies (White et al., 2017).
The clinical course of PCP is more severe in non-HIV patients
with increased length of hospital stay, higher rates of mechanical
ventilation and intensive care unit (ICU) admission compared
with HIV-infected patients (Roux et al., 2014; Sokulska et al.,
2015). Furthermore, a significant discrepancy in mortality rates
from PCP exists between HIV-infected patients and non-
HIV infected immunocompromised patients, 10–20 vs. 30–60%,
respectively (Morris and Norris, 2012; Stern et al., 2014; Kotani
et al., 2017).
The role of PCP prophylaxis in the HIV-negative
immunocompromised host is not well-established. A Cochrane
meta-analysis assessed the effectiveness of PCP prophylaxis
among non-HIV immunocompromised patients and tried to
define the type of immunocompromised patient that would
benefit from PCP prophylaxis (Stern et al., 2014). Thirteen
trials were included involving 1412 patients. These trials
included 520 children with acute lymphoblastic leukemia; the
remaining trials included adults with acute leukemia, solid organ
transplantation or bone marrow transplant recipients. There
was an 85% reduction in the occurrence of PCP in patients
receiving prophylaxis with Trimethoprim/sulfamethoxazole
(TMP/SMX) (RR of 0.15; 95% CI 0.04 to 0.62) compared to
no treatment. Many international reference networks have
published patient population-specific guidelines on when PCP
prophylaxis is indicated. In this observational retrospective
study, we investigate the proportion of patients admitted with
a diagnosis of PCP who did not receive proper prophylaxis
according to specific guidelines for HIV-positive, hematology
and solid organ transplant patients and hospital-specific
guidelines. (Maertens et al., 2016; Maschmeyer et al., 2016; White
et al., 2017)
METHODS
Study Design
We performed a retrospective multicenter cohort study in 3 large
tertiary referral centers (AZ Sint-Jan Bruges, Belgium; University
Hospital Ghent, Belgium and Erasmus University Medical
Centre, Rotterdam, The Netherlands). A list of patients 18 years
or older in whom a P. jirovecii real-time quantitative PCR (qPCR)
was performed on a BAL sample between September 2012
and March 2018, was retrieved from the clinical microbiology
laboratories of the three participating hospitals. Medical charts of
all patients were reviewed for data extraction. The Institutional
Review Boards of all sites approved the study.
Definition
All three centers use an in-house qPCR to diagnose PCP.
Diagnosing PCP usually depends on the histological or
microscopic identification of ascus (cysts containing ascospores)
and trophic forms in tissue, BAL or induced sputum using
specific staining methods like Wright’s-Giemsa or Grocott-
Fomori stains. However, these methods are labor intensive and
require specific expertise. Also, the fungal burden may vary
substantially, in particular in HIV-uninfected patients whichmay
limit the sensitivity of direct microscopy in these patients (Alanio
et al., 2011). A conventional PCR can detect low concentrations
of PJ DNA but low quantities of PJ DNA can be detected
in asymptomatic patients as well. With the development of
qPCR, it became possible to quantify the PJ load using the
semi-quantitative Cycle Threshold (Ct) values (Sing et al., 2000;
Alanio et al., 2011; Montesinos et al., 2017). Based on validation
studies using microscopically confirmed cases of PCP, thresholds
of Ct values have been proposed to differentiate between PCP
and colonization with a ‘gray zone‘ in between. Unfortunately,
most centers use an in house validated qPCR and therefore
the cut-off values used to rule PCP in or out often differ
between centers. The three clinical microbiology laboratories
all used an in-house developed qPCR method that all targeted
the mitochondrial rRNA (Desmet et al., 2009; Alanio et al.,
2011; Steensels et al., 2015). Although the methods differed
in primer-probe sequences and equipment for DNA extraction
and amplification, their results are very similar as the reported
semi-quantitative results by each of three laboratories for the
same external quality control scheme were nearly identical and
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because the internal validation procedure in each laboratory
resulted in similar cut off Ct-values to indicate probable PCP
(Ct value ≤ 28.5-30.0) and probable colonization with PJ (Ct
value > 34.0–35.0) (Table 1). These results demonstrate that the
analytical variation between the three laboratories was very small
and is neglectable compared with the biological variation and
the variation caused by differences in sampling (e.g., place and
volume of BAL). As a large range in Ct-values was considered an
indeterminate result regarding the discrimination of PCP from
PJ colonization, we applied the following case definitions for
patients for all three hospitals:
• A case of probable PCP is defined as a patient with a positive
qPCR result with a Ct value below the cut-off that was
considered strongly suggestive of a PCP used in each of the
centers (i.e., Ct 28.5–≤30, Table 1). Furthermore, the patient
should have received PCP therapy or the patient had died
without PCP therapy with respiratory failure contributing to
the death of the patient.
• A case of possible PCP was defined as a patient with positive
qPCR results with a Ct value ≤34-35 and both of the
following criteria: 1. A clinician’s judgement that the illness
was compatible with PCP based on the clinical and radiological
findings AND 2. The patient died with respiratory failure
contributing to the death of the patient or the patient received
treatment with co-trimoxazole or another anti-PCP therapy
(e.g., pentamidine IV, atovaquone) and survived.
• Patients with a positive qPCR result with a Ct value ≤34–35
that did not fulfill the definition of probable or possible PCP
and patients with a positive qPCR result but with Ct values
>34–35 were considered to be colonized with PJ.
Patients with no sufficient clinical data provided in the medical
chart were excluded. At the end of data collection all PCP cases
were reviewed by AD, AS, and BR.
Statistical Analysis
Statistical analysis included descriptive statistics including
numbers (percentages) and medians (ranges) for categorical
variables and continuous variables, respectively. Data were
reported as percentages for categorical variables and as mean
± standard deviation (SD) or median with interquartile range
(IQR) for continuous variables. Univariable statistical analysis
was performed using independent t-test or Mann–Whitney U-
test and Pearson’s chi-square test. All the tests of significance
were two-tailed and defined as p < 0.05 and analysis was
performed with SPSS version 21 (IBM, Armonk, NY, USA). The
following variables were registered for each patient: demographic
TABLE 1 | Interpretation of Ct value in each of the 3 centers regarding likelihood
of PCP.
Ct value interpretation Erasmuc MC AZ Sint-Jan UZ Gent
Strongly suggestive ≤29 ≤28.5 ≤30
Possible >29 and ≤34 >28.5 and ≤34 >30 and ≤35
Unlikely >34 and ≤40 >34 and ≤40 >35
Negative >40 >40 >40
parameters, underlying diseases, PCP prophylaxis (product, dose,
duration), glucocorticoid use (dose, duration), symptoms (fever,
dyspnea, nonproductive cough), duration hospital stay, ICU
admission and duration, mechanical ventilation, mortality, PCP
therapy, and prophylaxis indication following the guidelines
(White et al., 2017).
Prophylaxis
All patients were reviewed if they had received PCP prophylaxis
and if prophylaxis was indicated according to the appropriate
guidelines for prophylaxis and treatment of PCP. The following
guidelines were used: Center of Disease Control and Prevention,
the National Institutes of Health, and the HIV Medicine
Association of the Infectious Diseases Society of America
(Kaplan et al., 2009), European Conference on Infections in
Leukemia (Maertens et al., 2016) and the American Society
of Transplantation (Martin and Fishman, 2013; White et al.,
2017).
The local guideline was provided by the Erasmus Medical
Center and stated that prophylaxis should be given to the
following patient groups as seen in Table S1.
RESULTS
Between September 1, 2012, and May 31, 2018, a respiratory
tract specimen of 481 patients had a positive PJ qPCR test
result. 277 of these patients were excluded for further analysis
for the following reasons: age< 18 (n = 15), specimen tested
was not a BAL (n = 3), insufficient clinical data (n = 12),
FIGURE 1 | Overview of the inclusion process.
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Ct value >35 (n = 247). Two hundred and four patients
were retained for further analysis of which 153 were defined
as probable or possible PCP cases while 51 were considered
colonized. Of these 153 patients, 90 had a probable and
63 a possible PCP. Eleven of these 153 patients (7%) received
PCP prophylaxis according to guidelines while 142 (93%) did
not. According to the patient-specific guidelines, 133 (87%)
of the 153 patients had an indication for PCP prophylaxis
(Figures 1, 2). In Table S2, the proportion of patients per patient
group is shown that did not receive prophylaxis, although it
was indicated.
Patients characteristics of all 153 probable and possible PCP
cases can be found in Table S3. Mean age of all PCP patients
was 57 years (±16 SD), 69.3% were males and 39 (25.5%) were
HIV-positive. The non-HIV infected PCP patients consisted
of 50 (32.7%) hematology patients, 22 (14.4%) solid organ
transplantation recipients and 42 (27.4%) were patients with a
mix of other underlying diseases for which immunosuppressive
therapy had been initiated (Figure 3). A total of 82 (71.9%)
patients had received corticosteroids preceding the diagnosis of
PCP with a median duration of 30 (IQR [15–31]) days and a
median dosage of 24.5 ([12.5–40]) mg/day prednisone. The main
FIGURE 2 | Overview of the (non-)use of prophylaxis.
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FIGURE 3 | Incidence of PCP in the different PCP patient groups. *Other
patients; lung diseases (11), patients with malignancy other than hematology
(11), (metastatic) brain tumors (6), dermatology patients (4), auto-immune
diseases (4), rheumatoid arthritis (2), hyperthyroidism (1), mental health patient
(1), unknown (2).
reason for corticosteroid administration was SOT, allogeneic
stem cell transplant or metastatic disease of a solid organ cancer.
Overall, 11 (7.2%) patients received PCP prophylaxis of whom 5
patients used trimethoprim/sulfamethoxazole (TMP/SMX) and
the other 6 patients used atovaquone or pentamidine although
the retrospective nature of the study did not allow for the
evaluation of actual compliance with the prescribed prophylaxis.
133 (87%) patients of 153 cases did not receive prophylaxis as
indicated according to the local or population-specific guidelines.
The indication for prophylaxis was the use of corticosteroids in
the majority (74/133) of the cases. The median overall hospital
stay was 20 (IQR [11–35]) days and 14 (IQR [7–28]) days
after the PCP diagnosis. ICU admission was required in 58
(37.9%) patients with a median duration of 10 (IQR [4–16]) days.
Intubation and mechanical ventilation was required in 41 of the
153 (71%) with a median duration of 7 (IQR [4–16]) days. In
total, 29 of the 153 patients with PCP (19%) died before hospital
discharge. Adjunctive corticosteroid therapy was prescribed in 14
of the 29 (48.3%) patients that died. Mortality of patients with
and without adjunctive corticosteroid therapy was similar at 13
and 16%, respectively.
A higher proportion of the HIV uninfected patients were
admitted to the ICU and required mechanical ventilation
(Table S4). Overall, 29 of the patients diagnosed with PCP died
and 26 of them were HIV uninfected.
DISCUSSION
With the current study, we aimed to describe the epidemiology
of PCP in patients admitted to three large tertiary care centers in
a resource-rich setting. In particular, we focused on compliance
with guidelines on the use of PCP prophylaxis preceding the
PCP diagnosis. We classified patients into a probable or possible
PCP, based on clinical and qPCR results. Of the 153 patients
identified, 75% were immunocompromised due to an underlying
disease other than HIV. This shift toward HIV-negative
immunocompromised patients was described previously and
is not surprising in the Netherlands and Belgium. Indeed,
the WHO 90/90/90 goal regarding HIV management, defined
as 90% of prevalent HIV infections being diagnosed, 90% of
diagnosed cases on treatment and 90% of treated patients having
an undetectable viral load, has already been achieved in both
countries (Avino et al., 2016;White et al., 2017; van der Valk et al.,
2019).
The key observation of our study was that 133 of the 153
patients (87%) diagnosed with PCP had not received prophylaxis
while they had an indication for it according to patient-
specific guidelines. However, the effectivity of prophylaxis is
without a doubt. Indeed, a Cochranemeta-analysis demonstrated
that prophylaxis is very effective with a relative risk for PCP
of 0.15 when Trimethoprim/sulfamethoxazole (TMP/SMX) is
used (Stern et al., 2014). We agree however that the severity
of immunosuppression above which prophylaxis is required
remains a matter of debate. While the importance of prophylaxis
for patients with HIV not on cART and with a CD4 count
below 200 cells/µL is without a doubt, the dose and duration
of corticosteroid therapy above which the dose and duration of
corticosteroid therapy above which the benefit to risk ratio of
PCP prophylaxis becomes positive is not well-established. To
generate these data, a large cohort of patients on corticosteroid
therapy, while not on PCP prophylaxis should be followed over
a long enough time to define the PCP incidence per 100 years
of follow-up at a particular cumulative and daily corticosteroid
dose. This is a challenging exercise which the current data,
unfortunately, did not allow to do. Fortunately, Park JW et al.
very recently described the results of a large retrospective study
on the incidence of PCP in patients with rheumatic diseases on
corticosteroid therapy (Park et al., 2018, 2019). They found an
incidence of PCP of 2.4 per 100 person-years of follow-up for
patients receiving a daily dose of >30mg prednisone equivalent
and 0.5 per 100 person-years in those on a dose of 15-30mg
per day. In the latter group, 4 of the 5 patients with PCP had
to receive concomitant steroid pulse therapy on top of the daily
dose. Therefore, when these pulse therapies are included in the
calculation of the mean daily prednisone dose, 4 of the 5 patients
with PCP could be considered to have received a dose >30mg
per day and the 5th patient had as an important additional risk
factor an absolute lymphocyte count <200 cells/µL. Therefore, a
30mg threshold above which PCP prophylaxis is indicated may
be reasonable as long as steroid pulse therapy is considered a risk
factor as well.
But even if a consensus can be reached on the dose above
which the benefits of PCP prophylaxis outweigh the risk of
prophylaxis, other barriers toward improved compliance with
PCP prophylaxis remain to be tackled. Indeed, despite the fact
that local PCP guidelines were in place also for non-SOT non-
hematology patients on corticosteroids above the dose described
in Table S1 at one of the 3 hospitals of our study, prophylaxis
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 May 2020 | Volume 10 | Article 224
Dunbar et al. Pneumocystis jirovecii Pneumonia
was not used in the majority of these PCP cases. Given the
broad use of corticosteroids as immunosuppressive drug across
a wide range of diseases covered by many medical specialties,
it is challenging to make every clinician aware of when PCP
prophylaxis is indicated. If digital medication orders are used,
an automatic reminder on the use of PCP prophylaxis that
pops up when corticosteroids are prescribed above a certain
dose comparable to drug-drug interaction warningsmay improve
compliance with prophylaxis. But even then, overload of these
warnings may lead to fatigue and eventually not lead to the
desired effect. Therefore, awareness of the problem is needed. But
even then, clinicians may remain reluctant regarding the use of
prophylaxis due to the lack of conclusive evidence on when the
benefit-risk ratio of PCP prophylaxis becomes positive.
Unfortunately, the onset of PCP in HIV-negative patients is
often abrupt with respiratory failure at the time of diagnosis
(Morris and Norris, 2012). The higher mortality (22.8%) that
we observed in the HIV-negative patients compared with the
HIV-infected (7.7%) and the longer hospital stay illustrated this.
Our study has its limitations. Given its retrospective nature,
we were unable to assess the reasons for the non-use of
prophylaxis by the treating physician. Also, the classification
of cases into probable and possible PCP is somewhat arbitrary
and the qPCR Ct values used in each of the hospitals differed
slightly. However, we tried to use definitions that match clinical
practice as much as possible. Also, a BAL procedure is often
not standardized regarding the location inside the lung where
sampling is performed nor the volume that is instilled and
aspirated. As already discussed above, the second limitation
of our study is the criteria used regarding PCP prophylaxis
being defined as indicated for the HIV-uninfected, non-
hematology, non-SOT patients. The guideline used at Erasmus
MC regarding PCP prophylaxis in this very heterogeneous
group of immunocompromised patients was based on expert
opinion and limited retrospective observational data rather than
conclusive evidence from prospective clinical trials. It states
that prophylaxis is indicated when prednisone at a dose of
>20mg is given for >21 days. Given the recent results by
Park JW et al. already discussed in detail above, a 30mg
threshold may be more appropriate as long as pulse therapy with
corticosteroids is included in the calculation of the daily dose.
Finally, although we feel that the 3 hospitals are representative
of tertiary care hospitals in Belgium and the Netherlands,
compliance with PCP prophylaxis guidelines may be better in
other hospitals.
In summary, in our case series, the majority of patients
diagnosed with PCP in recent years had not received
PCP prophylaxis even though patient-specific guidelines
recommending prophylaxis were available for most. PCP was
mostly diagnosed in HIV-negative patients and mortality in this
population was high. Awareness of the risk of corticosteroid-
based immunosuppressive therapy should increase, in particular
among sporadic prescribers. Automatic warning systems
incorporated in electronic patient files and/or digital medication
prescription systems could facilitate this and should be studied.
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